■ MANTIS

CDMO & Bioprocess
Sector Intelligence
Updated 18 April 2026  ·  67 companies monitored
1,047
Signals
30 days
67
Companies
tracked
31
Convergence
alerts active
71
Predictions
tracked
Leading narrative CDMO M&A Consolidation Rolling 7 days
Leading tech themeSmall MoleculePatent & publication signals · 30 days
Story of the week
→ Steady CDMO M&A Consolidation
503signals this week · 46companies active
Narrative tracker — signals · rolling 7 days
01CDMO M&A Consolidation503
02GLP-1 Manufacturing Capacity263
03FDA / Regulatory Pressure150
04Cell & Gene Therapy CDMO Consolidation216
05Biosimilar Market Expansion198
06CDMO Capacity Buildout138
07ADC Outsourcing Wave76
08Next-Gen Manufacturing Technology59
09Nucleic Acid Manufacturing19
10BIOSECURE Act / China De-risking28
Narrative momentum — rolling 30 days
Narrative momentum — 30 days

Each line tracks one sector narrative — 7-day rolling average of signal volume and cross-source breadth, updated daily.

This week in CDMO & bioprocess
📰Lilly to acquire CrossBridge Bio for up to $300mEli Lillypharmaceutical-technology.comM&A 📰Lilly makes preclinical ADC specialist CrossBridge its latest acquisition in vague $300M dealEli Lillyfiercebiotech.comM&A 📰FDA tells Eli Lilly to round up more safety info on key obesity launch FoundayoEli Lillyfiercepharma.comRegulatory 📰BMS and Oxford BioTherapeutics join forces in TCE discovery pactOxford Biomedicapharmaceutical-technology.comPartnership 📰Boehringer Ingelheim and Zai Lab team up for dual DLL3 therapy studyBoehringer Ingelheim Biopharmaceuticalspharmaceutical-technology.comPartnership 📰Novo Nordisk and OpenAI forge alliance to drive speedy drug developmentNovo Nordiskpharmaceutical-technology.comPartnership 📰Insilico CEO sees potentially $2.75 billion collaboration as ‘fusing Lilly’s clinical excellence’ with Insilico’s ‘end-to-end AI engine’Eli Lillydrugdiscoverytrends.comPartnership 📰Pfizer–backed Storm blows into $56M series C, launches phase 2 sarcoma trialPfizerfiercebiotech.comRegulatory 📰Merck unveils PD-1xVEGF bispecific data in NSCLC, remains tight-lipped on phase 3 plansMerck KGaAfiercebiotech.comPartnership 📰Lilly debuts more Foundayo data as FDA requests post-marketing trialsEli Lillypharmaceutical-technology.com
Signal of the week
FDA Action ●●●●○○○○  4/10
Drug Approval: CARBAMAZEPINE (manufactured by Torrent Pharmaceuticals)
How it works
01
Collect
Signals ingested daily across patents, clinical trials, FDA and EMA regulatory filings, scientific publications, SEC disclosures, hiring patterns, and industry news. Each signal is scored and classified by therapy area and signal type.
02
Converge
When multiple independent sources flag the same company within a rolling window, a convergence alert fires. Cross-source agreement is the signal — a single news article is noise; a patent filing, a hiring surge, and a regulatory action on the same company are not.
03
Synthesise
A weekly synthesis covers what moved, what it implies, and where to look next. Predictions are made explicitly and logged — then scored as outcomes become known, building a calibration record over time.
Signal sources — rolling 30 days
News612
Clinical Trials209
Science97
FDA89
Hiring34
SEC Filings6

Mantis runs continuously — ingesting signals, scoring convergence, and tracking whether its predictions come true. It does not summarise headlines. It identifies when independent data sources start moving in the same direction on the same company, and asks what that combination of evidence implies.

The weekly briefing
Available on request.
[email protected] →
[email protected] © 2026 Mantis Intelligence.

Mantis Intelligence is not authorised or regulated by the Financial Conduct Authority or any other financial regulator. Content is produced by automated systems and artificial intelligence for information and research purposes only. Nothing on this site constitutes investment advice, a personal recommendation, or a solicitation. Past signal patterns are not predictive of future events or outcomes.